cabotegravir and rilpivirine

Action and Spectrum

Drug Interaction

Adverse Reaction

>10%: 

Reaction at the site of injection 

1-10%: 

Pyrexia  

Fatigue  

Headache  

Musculoskeletal pain  

Nausea  

Sleep disorders  

Dizziness 

Rash 

Black Box Warning

Contraindication / Caution

Cabotegravir/rilpivirine is contraindicated in patients hypersensitive to the active ingredient. 

Pregnancy / Lactation

Pregnancy consideration:  

Insufficient data is available regarding the use of the drug in pregnant females. 

Breastfeeding warnings:  

No data is available regarding the excretion of the drug in breast milk. 

Pregnancy category: 

• Category A: well-controlled and Satisfactory studies do not show risk to the fetus in the first/later trimester.        
• Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women        
• Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.       
• Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.        
• Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.        
• Category N: There is no data available for the drug under this category 

Pharmacology

Adminstartion

Patient Information Leaflet

Patient information leaflet 

Generic Name: cabotegravir/rilpivirine 

Pronounced: cab-o-teg-rav-ir/ril-pi-vir-ine 

Why do we use cabotegravir/rilpivirine? 

Cabotegravir/rilpivirine is an antiviral (integrase inhibitor) drug. It is used to treat HIV infection.